| Sinae Angela Kane, MD | |
|
350 Parnassus Ave Ste 400, San Francisco, CA 94117-3608 | |
| (415) 564-1261 | |
| Not Available |
| Full Name | Sinae Angela Kane |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 13 Years |
| Location | 350 Parnassus Ave Ste 400, San Francisco, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003106014 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 142792 (California) | Primary |
| 207NS0135X | Dermatology - Procedural Dermatology | 142792 (California) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greenbrae Dermatology, A Medical Corporation | 4789832908 | 4 |
News Archive
A team of researchers at the University of California, Riverside, seeking to upend a long-held theory explaining how hormones freely enter and exit cells, has received a major boost in the form of a $1 million award from the W. M. Keck Foundation.
Increasing access. Improving quality and efficiency. Lowering costs. When GE launched its healthymagination initiative last year, these were the long-term goals and at RSNA 2010, GE Healthcare will highlight a variety of technologies developed to support this strategy and help improve patient care worldwide.
Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease?
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
› Verified 1 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
A team of researchers at the University of California, Riverside, seeking to upend a long-held theory explaining how hormones freely enter and exit cells, has received a major boost in the form of a $1 million award from the W. M. Keck Foundation.
Increasing access. Improving quality and efficiency. Lowering costs. When GE launched its healthymagination initiative last year, these were the long-term goals and at RSNA 2010, GE Healthcare will highlight a variety of technologies developed to support this strategy and help improve patient care worldwide.
Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease?
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
› Verified 1 days ago
| Entity Name | Greenbrae Dermatology, A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174898654 PECOS PAC ID: 4789832908 Enrollment ID: O20130123000375 |
News Archive
A team of researchers at the University of California, Riverside, seeking to upend a long-held theory explaining how hormones freely enter and exit cells, has received a major boost in the form of a $1 million award from the W. M. Keck Foundation.
Increasing access. Improving quality and efficiency. Lowering costs. When GE launched its healthymagination initiative last year, these were the long-term goals and at RSNA 2010, GE Healthcare will highlight a variety of technologies developed to support this strategy and help improve patient care worldwide.
Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease?
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sinae Angela Kane, MD 350 Parnassus Ave Ste 400, San Francisco, CA 94117-3608 Ph: (415) 564-1261 | Sinae Angela Kane, MD 350 Parnassus Ave Ste 400, San Francisco, CA 94117-3608 Ph: (415) 564-1261 |
News Archive
A team of researchers at the University of California, Riverside, seeking to upend a long-held theory explaining how hormones freely enter and exit cells, has received a major boost in the form of a $1 million award from the W. M. Keck Foundation.
Increasing access. Improving quality and efficiency. Lowering costs. When GE launched its healthymagination initiative last year, these were the long-term goals and at RSNA 2010, GE Healthcare will highlight a variety of technologies developed to support this strategy and help improve patient care worldwide.
Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease?
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
› Verified 1 days ago
Edwin Yuen, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 199 Ocean Ave, San Francisco, CA 94112 Phone: 415-585-7771 Fax: 415-585-1117 | |
Joel Alan Teisch, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1001 Potrero Ave, Bldg 90 Ward 92 Rm 224, San Francisco, CA 94110 Phone: 415-206-8680 Fax: 415-206-4317 | |
Malcolm Nehemiah Pyles, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1 Daniel Burnham Ct Ste 350c, San Francisco, CA 94109 Phone: 415-771-6300 | |
Deirdre Alexander, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3905 Sacramento St, 201, San Francisco, CA 94118 Phone: 415-387-8007 | |
Dr. Cynthia Lea Chen, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 1701 Divisadero St, Third Floor, San Francisco, CA 94115 Phone: 415-353-7800 Fax: 415-353-7870 | |
Michael K Burns, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 450 Sutter St, #932, San Francisco, CA 94108 Phone: 415-362-4565 Fax: 415-362-4562 |